


# Unlocking The Potential of **Bacteriophages**



# WHO WE ARE

Aziya Immunopreparat LLC (est. 2013) is a pioneering pharmaceutical company dedicated to the development and production of **bacteriophage-based medicines**.

As one of the first in the world to implement **GMP standards** for bacteriophage manufacturing, we are at the forefront of antibiotic-free treatment innovation.



# OUR VISION & MISSION

## *Vision*

A future where bacteriophage technology revolutionizes healthcare, food safety, agriculture, and veterinary care, providing natural and sustainable alternatives to antibiotics.

## *Mission*

To combat bacterial infections with precise, effective, and eco-friendly solutions, reducing antibiotic resistance and improving global health.



### Pharmaceuticals:

Safe, effective, antibiotic-free treatments



### Food Safety:

Protecting products from harmful bacteria



### Agricultural Products:

Innovative solutions for farming & livestock



### Cosmetics:

Science-backed, safe skincare products



### Veterinary:

Natural health solutions for animals



SUCCESSFULLY PASSED FROM  
CLINICAL TRIALS IN ACCORDANCE  
WITH **GCP STANDARDS**




# THE DAM BREAK IN UZBEKISTAN ON JUNE 23, 2020

A dam failure in Sardoba, Central Asia, led to severe flooding, affecting over **35,000 hectares in Uzbekistan and Kazakhstan**. Experts estimated water loss exceeding 500 million cubic meters (m<sup>3</sup>), increasing the risk of bacteriological infections. To prevent an epidemic, the **Department of Sanitary and Epidemiological Welfare** of Uzbekistan implemented phage therapy, administering **Bacteriophage Dysentery Polyvalent “MediPhage” 20 ml** (a liquid formulation for oral and rectal use), produced by Aziya Immunopreparat (Mediphage).

The bacteriophage underwent clinical trials in 2017 at City Infectious Diseases Hospital No. 5 and has been effectively combating infections and antibiotic resistance.

**Aziya Immunopreparat now supplies its products internationally, delivering liquid formulations and capsules to Asia, Europe, and North America.**



# EXECUTIVE TEAM



**Shukrulloh  
Kasimov**

*Co-Founder &  
General Director*



**Mirkamol  
Mirsaliev**

*Co-Founder & Chief Director  
of Strategic Development*



**Alimdjan  
Ikramov**

*Chief Technology  
Officer (CTO)*



**Akmal  
Khatamov**

*Strategic operations &  
business development.*



**Fatkhulloh  
Kakhramonov**

*Director of  
Productions*

# PARTNERS



# OUR BRANDS



MediPhage™

KEM-Phage™

KEM-Phage-Food™

KEM-Phage-Agro™

KEM-Phage-Cosmetic™

LarPhage™




# PROBLEM

**Antibiotic resistance is a growing global health crisis.**

According to WHO:

- **1.27 million deaths** in 2019
- Projected **10M deaths** annually **by 2050**



# A portfolio of biologically active supplements based on bacteriophages



**Infectoff liquid for oral administration 10 ml / 20 ml / 100 ml**

## Purpose

- selective destruction of pathogenic bacteria;
- maintaining intestinal microflora balance;
- growth of beneficial microflora and reduction of inflammatory processes;
- activation of innate immunity, strengthening the barrier functions of mucous membranes;
- additional support for the body during periods of increased stress (including in children, the elderly, and frequently ill people).



**Sanafag liquid for oral administration 10 ml / 20 ml / 100 ml**

## Purpose

- selective destruction of pathogenic bacteria;
- maintaining intestinal microflora balance;
- growth of beneficial microflora and reduction of inflammatory processes;
- activation of innate immunity, strengthening the barrier functions of mucous membranes;
- additional support for the body during periods of increased stress (including in children, the elderly, and frequently ill people).



**Nanophage liquid for oral administration 10 ml / 20 ml / 100 ml / Nanophage spray 20 ml**

## Purpose

- selectively destroys pathogenic and opportunistic bacteria;
- helps maintain the natural microbial balance in the mouth, nose, and throat;
- reduces discomfort associated with inflammation of the throat, nose, or ears;
- activates innate immunity and strengthens the barrier function of the mucous membranes.



**Lorophage liquid for oral administration 10 ml / 20 ml / 100 ml**

## Purpose

- Helps care for minor cuts, abrasions, and mild burns;
- Selectively destroys pathogenic and opportunistic bacteria;
- Helps maintain the natural microbial balance in the mouth, throat, and nose;
- Reduces discomfort associated with inflammation of the throat, nose, or ears;
- Activates innate immunity and strengthens the barrier function of the mucous membranes.



**Elifag liquid for oral administration 10 ml / 20 ml / 100 ml / Elifag spray 20 ml**

## Purpose

- Helps care for minor cuts, abrasions, and mild burns;
- Selectively destroys pathogenic and opportunistic bacteria;
- Helps maintain the natural microbial balance in the mouth, nose, and throat;
- Reduces discomfort associated with inflammation of the throat, nose, or ears;
- Activates innate immunity and strengthens the barrier function of the mucous membranes.

# List of medicinal products based on bacteriophages



**Primaphage neo 10 ml No. 5**  
**Primaphage neo 20 ml No. 4**  
**Primaphage neo 100 ml No. 100**

## Treatment:

- surgical infections: purulent wound, burn, abscess, phlegmon, boil, carbuncle, hydradenitis, panaritium, paraproctitis, mastitis, bursitis and osteomyelitis;
- Urogenital infections: urethritis, cystitis, pyelonephritis, colpitis, endometritis and salpingoophoritis;
- bacterial infections of the upper respiratory tract: purulent-inflammatory diseases of the ear, throat, nose, sinuses, mouth, pharynx, larynx, bronchi, lungs and pleura (otitis media, sore throat, pharyngitis, laryngitis, stomatitis, sinusitis, periodontitis, sinusitis, bronchitis, pneumonia, pleurisy);
- purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, bacterial sepsis, etc.);
- gastroenterological diseases: enterocolitis, cholecystitis, irritable bowel syndrome (IBS), dysbiosis;
- generalized bacterial septic diseases;
- other diseases caused by Staphylococcus haemolyticus, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, Enterococcus faecalis and various Escherichia coli serogroups.

## Prevention:

- treatment of fresh wounds;
- purulent complications during surgical procedures and operations;
- bacterial complications in acute respiratory viral diseases;
- bacterial sepsis and enterocolitis in newborns with intrauterine infection;
- bacterial contamination and nosocomial infections in medical institutions.



**Primafag neo  
 spray 100 ml**

## Treatment:

- surgical infections: purulent wound, burn, abscess, phlegmon, boil, carbuncle, hydradenitis, panaritium, paraproctitis, mastitis.
- bacterial infections of the upper respiratory tract: purulent-inflammatory diseases of the ear, throat, nose, sinuses, mouth, pharynx, larynx (otitis media, sore throat, pharyngitis, laryngitis, stomatitis, sinusitis, periodontitis, sinusitis).
- purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis).

## Prevention:

- treatment of fresh wounds;
- purulent complications during surgical procedures and operations.



**Polyvalent Curafag 10 ml No. 5**  
**Polyvalent Curafag 20 ml No. 4**  
**Polyvalent Curafag 100 ml No. 1**

## Treatment:

- surgical infections: purulent wound, burn, abscess, phlegmon, boil, carbuncle, hydradenitis, panaritium, paraproctitis, mastitis, bursitis and osteomyelitis;
- Urogenital infections: urethritis, cystitis, pyelonephritis, colpitis, endometritis and salpingoophoritis;
- bacterial infections of the upper respiratory tract: purulent-inflammatory diseases of the ear, throat, nose, sinuses, mouth, pharynx, larynx, bronchi, lungs and pleura (otitis media, sore throat, pharyngitis, laryngitis, stomatitis, sinusitis, periodontitis, sinusitis, bronchitis, pneumonia, pleurisy);
- purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, bacterial sepsis, etc.);
- gastroenterological diseases: enterocolitis, cholecystitis, irritable bowel syndrome (IBS), dysbiosis;
- generalized bacterial septic diseases;
- other diseases caused by Streptococcus spp., Staphylococcus aureus, Pseudomonas aeruginosa, Proteus mirabilis and various Escherichia coli serogroups.

## Prevention:

- treatment of fresh wounds;
- purulent complications during surgical procedures and operations;
- bacterial complications in acute respiratory viral diseases;
- bacterial sepsis and enterocolitis in newborns with intrauterine infection;
- bacterial contamination and nosocomial infections in medical institutions.

# List of medicinal products based on bacteriophages



**Kurafag polyvalent spray  
20 ml No. 1**

**Treatment:**

- surgical infections: purulent wound, burn, abscess, phlegmon, boil, carbuncle, hydradenitis, panaritium, paraproctitis, mastitis;
- bacterial infections of the upper respiratory tract: purulent-inflammatory diseases of the ear, throat, nose, sinuses, mouth, pharynx, larynx, (otitis media, sore throat, pharyngitis, laryngitis, stomatitis, sinusitis, periodontitis, sinusitis);
- purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis).

**Prevention:**

- treatment of fresh wounds;
- purulent complications during surgical procedures and operations.



**Polyvalent innophagus 10 ml  
Innofag polyvalent 20 ml  
Innofag polyvalent 100 ml**

**Treatment:**

- surgical infections: purulent wound, burn, abscess, phlegmon, boil, carbuncle, hydradenitis, panaritium, paraproctitis, mastitis, bursitis and osteomyelitis;
- urogenital infections: urethritis, cystitis, pyelonephritis, colpitis, endometritis and salpingoophoritis;
- bacterial infections of the upper respiratory tract: purulent-inflammatory diseases of the ear, throat, nose, sinuses, mouth, pharynx, larynx, bronchi, lungs and pleura (otitis media, sore throat, pharyngitis, laryngitis, stomatitis, sinusitis, periodontitis, sinusitis, bronchitis, pneumonia, pleurisy);
- purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, bacterial sepsis, etc.);
- gastroenterological diseases: enterocolitis, cholecystitis, irritable bowel syndrome (IBS), dysbiosis;
- generalized bacterial septic diseases;
- other diseases caused by Staphylococcus spp., Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, Streptococcus spp. and the various serogroups of Escherichia coli

**Prevention:**

- treatment of fresh wounds;
- purulent complications during surgical procedures and operations;
- bacterial complications in acute respiratory viral diseases;
- bacterial sepsis and enterocolitis in newborns with intrauterine infection;
- bacterial contamination and nosocomial infections in medical institutions.



**Innofag polyvalent  
spray 20 ml No. 1**

**Treatment:**

- surgical infections: purulent wound, burn, abscess, phlegmon, boil, carbuncle, hydradenitis, panaritium, paraproctitis, mastitis;
- bacterial infections of the upper respiratory tract: purulent-inflammatory diseases of the ear, throat, nose, sinuses, mouth, pharynx, larynx, (otitis media, sore throat, pharyngitis, laryngitis, stomatitis, sinusitis, periodontitis, sinusitis);
- purulent-inflammatory diseases of newborns (omphalitis, pyodermitis, conjunctivitis).

**Prevention:**

- treatment of fresh wounds;
- purulent complications during surgical procedures and operations.

# List of medicinal products based on bacteriophages



**Phageco polyvalent 10 ml**  
**Phageco polyvalent 20 ml**  
**Phageco polyvalent 100 ml**

**Purpose:**

- salmonellosis;
- bacterial dysentery;
- acute diarrhea;
- dyspepsia;
- dysbiosis;
- irritable bowel syndrome (IBS);
- infectious gastritis: gastroenteritis, gastroenterocolitis, enteritis, enterocolitis and colitis;
- treatment of patients in all age and high-risk groups;
- rehabilitation of convalescents (bacterial carrier);
- prevention of gastrointestinal tract infections.



**Bacteriophage dysentery liquid 20 ml**  
**No. 4**  
**Bacteriophage dysentery capsule N°4 /**  
**N°8 / N°10 / N°20**

**Treatment:**

- treatment of patients diagnosed with acute diarrhea with colic syndrome and bacterial dysentery in all age and high-risk groups;
- rehabilitation of convalescents (bacterial carrier);
- prevention of bacterial dysentery.



**Polyvalent Lysiphage 10 ml No. 5**  
**Polyvalent Lysiphage 20 ml No. 4**  
**Polyvalent Lysiphage 100 ml No. 1**

**Treatment:**

- surgical infections: purulent wound, burn, abscess, phlegmon, boil, carbuncle, hydradenitis, panaritium, paraproctitis, mastitis, bursitis and osteomyelitis;
- Urogenital infections: urethritis, cystitis, pyelonephritis, colpitis, endometritis and salpingoophoritis;
- bacterial infections of the upper respiratory tract: purulent-inflammatory diseases of the ear, throat, nose, sinuses, mouth, pharynx, larynx, bronchi, lungs and pleura (otitis media, sore throat, pharyngitis, laryngitis, stomatitis, sinusitis, periodontitis, sinusitis, bronchitis, pneumonia, pleurisy);
- purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, bacterial sepsis, etc.);
- gastroenterological diseases: enterocolitis, cholecystitis, irritable bowel syndrome (IBS), dysbiosis;
- generalized bacterial septic diseases;
- other diseases caused by Staphylococcus haemolyticus, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, Enterococcus faecalis and various Escherichia coli serogroups.

**Prevention:**

- treatment of fresh wounds;
- purulent complications during surgical procedures and operations;
- bacterial complications in acute respiratory viral diseases;
- bacterial sepsis and enterocolitis in newborns with intrauterine infection;
- bacterial contamination and nosocomial infections in medical institutions.



**Lysiphage polyvalent spray 20 ml**

**Treatment:**

- surgical infections: purulent wound, burn, abscess, phlegmon, boil, carbuncle, hydradenitis, panaritium, paraproctitis, mastitis, bursitis and osteomyelitis;
- Urogenital infections: urethritis, cystitis, pyelonephritis, colpitis, endometritis and salpingoophoritis;
- bacterial infections of the upper respiratory tract: purulent-inflammatory diseases of the ear, throat, nose, sinuses, mouth, pharynx, larynx, bronchi, lungs and pleura (otitis media, sore throat, pharyngitis, laryngitis, stomatitis, sinusitis, periodontitis, sinusitis, bronchitis, pneumonia, pleurisy);
- purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, bacterial sepsis, etc.);
- gastroenterological diseases: enterocolitis, cholecystitis, irritable bowel syndrome (IBS), dysbiosis;
- generalized bacterial septic diseases;
- other diseases caused by Staphylococcus haemolyticus, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, Enterococcus faecalis and various Escherichia coli serogroups.

**Prevention:**

- treatment of fresh wounds;
- purulent complications during surgical procedures and operations;
- bacterial complications in acute respiratory viral diseases;
- bacterial sepsis and enterocolitis in newborns with intrauterine infection;
- bacterial contamination and nosocomial infections in medical institutions.

# OUR SOLUTIONS

## Bacteriophage-Based Medicines



Spray for oral & external use



Sterile liquid for oral use

### Treatable Conditions:

- Infectious Gastritis
- Gastroenteritis
- Gastroenterocolitis
- Enteritis
- Colitis
- Enterocolitis
- Urinary system

### Targeted Pathogens:

- *Salmonella* spp. (*S. newport*, *S. enteritidis*, *S. moscow*, *S. paratyphi B*, *S. agama*, *S. java*)
- *Shigella* spp. (*Sh. sonnei*, *Sh. flexneri* serovars I, II, III, VI, *Sh. boydii*)
- *Proteus* spp.
- *Staphylococcus aureus*
- *Pseudomonas aeruginosa*
- *Pathogenic Escherichia coli*
- *Staphylococcus haemolyticus*
- *Enterococcus faecalis*
- *Klebsiella pneumoniae*
- *Streptococcus thermophilus*



# OUR SOLUTIONS

## Bacteriophage-Based Food Supplements



Capsule



Capsule

### Treatable Conditions:

- Infectious Gastritis
- Gastroenteritis
- Gastroenterocolitis
- Enteritis
- Colitis
- Enterocolitis
- Urinary system

### Targeted Pathogens:

- *Salmonella* spp. (*S. newport*, *S. enteritidis*, *S. moscow*, *S. paratyphi B*, *S. agama*, *S. java*)
- *Shigella* spp. (*Sh. sonnei*, *Sh. flexneri* serovars I, II, III, VI, *Sh. boydii*)
- *Proteus* spp.
- *Staphylococcus aureus*
- *Pseudomonas aeruginosa*
- *Pathogenic Escherichia coli*
- *Staphylococcus haemolyticus*
- *Enterococcus faecalis*
- *Klebsiella pneumoniae*
- *Streptococcus thermophilus*



# OUR SOLUTIONS



## Advanced Skin Care Innovation with Bacteriophages

### The formula combines:

- Active phages against Staphylococcus spp.
- Deep hydration and skin barrier restoration
- Brightening and wrinkle care
- Even skin tone and natural radiance

AcPhage™ is manufactured in South Korea:

- ✓ Dermatologically tested
- ✓ Hypoallergenic
- ✓ Meets international standards



APPROVED BY THE  
MINISTRY OF HEALTH  
OF REP. OF UZBEKISTAN

**Treatment for Skin problems  
caused by Staphylococcus spp.  
often underlie acne, inflammation,  
and irritation.**

**Helps with Hidradenitis  
Suppurativa, Acne (Acne Vulgaris),  
Folliculitis, Carbuncles, Furuncles,  
Impetigo, Neonatal Pemphigus.**



# OUR SOLUTIONS


## Innovative Gut & Immune Health Solution for Cats & Dogs

### Indications:

- Clinically relevant probiotics
- Designed for veterinary practice
- Support of microflora and immunity
- Restores microflora after antibiotics
- Reducing the risk of dysbiosis

### Composition:

- Enterococcus faecium EF-BMPMC-2147
- Lactobacillus plantarum LP-BMPMC-1836
- Saccharomyces cerevisiae SC-BMPMC-3274
- Bacillus subtilis BS-BMPMC-4512
- Bifidobacterium animalis BA-BMPMC-2698



# OUR SOLUTIONS


## Innovative Gut & Immune Health Solution for Cats & Dogs

### Indications:

- Probiotics + bacteriophages
- Supports the digestive system and immunity
- Restores microflora after antibiotics
- Naturally affects harmful bacteria

### Composition:

Staphylococcus, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus faecium, EF-BMPMC-2147; Lactobacillus plantarum LP-BMPMC-1836; Saccharomyces cerevisiae SC-BMPMC-3274; Bacillus subtilis BS- BMPMC-4512; Bifidobacterium animalis BA-BMPMC-2698



# OUR SOLUTIONS

## Innovative Gut & Immune Health Solution for Dogs

### Indications:

- Acute & chronic gastroenteritis
- Bacterial diarrhea
- Colibacillosis, skin & intestinal staph infections
- Dysbiosis after antibiotic therapy
- Infection prevention during stress or diet change

### Composition:

Bacteriophages against: *E. coli*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Klebsiella pneumoniae*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Enterococcus faecalis*, *Enterobacter cloacae*  
Probiotics (dry form only): *Lactobacillus acidophilus*, *Bifidobacterium bifidum*, *Enterococcus faecium*



# OUR SOLUTIONS

## An Innovative Approach to **Feline Digestive & Immune Support in Cats**

### Indications:

- Infectious diarrhea
- Intestinal dysbiosis
- Colibacillosis
- Immunity support after illness or vaccination
- Improves digestion & appetite during diet changes

### Composition:

Bacteriophages against: E. coli, Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, Proteus vulgaris, Pseudomonas aeruginosa, Enterococcus faecalis, Enterobacter cloacae  
Probiotics (dry form only): Lactobacillus acidophilus, Bifidobacterium bifidum, Enterococcus faecium



# OUR SOLUTIONS

## Innovative Protection Against **Enteric Infections** in Poultry

### Indications:

- Colibacillosis, salmonellosis
- Bacterial enteritis
- Staphylococcosis
- Digestive disorders & chick mortality
- Prevents gut infections in intensive farming

### Composition:

Bacteriophages against: *E. coli*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Klebsiella pneumoniae*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Enterococcus faecalis*, *Enterobacter cloacae*  
Probiotics (dry form only): *Lactobacillus acidophilus*, *Bifidobacterium bifidum*, *Enterococcus faecium*



# OUR SOLUTIONS

## Aquaculture Innovation: Natural Defense **Against Bacterial Infections**

### Indications:

- Aeromonosis, pseudomonosis
- Bacterial enteritis in cultured fish
- Infections due to overcrowding
- Reduces stress during transport
- Prevents juvenile mortality

### Composition:

Bacteriophages against: *E. coli*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Klebsiella pneumoniae*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Enterococcus faecalis*, *Enterobacter cloacae*  
Probiotics (dry form only): *Lactobacillus acidophilus*, *Bifidobacterium bifidum*, *Enterococcus faecium*



# OUR SOLUTIONS

## Advanced **Disinfection** and Protection!

### Key Benefits

- Disinfects staphylococcal infections in veterinarians and pet caregivers.
- Also used to sanitize pet toys for staphylococci protection.
- Recommended for air disinfection in offices to eliminate bacteria.
- Can be sprayed on hands for antibacterial protection.

*To use mix the capsule with drinking water at a 1:150 ratio (1 capsule to 150ml water)*



# OUR SOLUTIONS

## Meat Protection Concentrate for Beef, Lamb & Poultry

### Key Benefits

Provides prophylactic protection for those in regular contact with animals and birds carrying infections.

Effectively disinfects hands, equipment, and workspaces, making it ideal for;

- veterinarians,
- butchers,
- dairy workers,
- food industry staff,
- caregivers.

### How-to use:

Mix the Concentrate with water at a 1:150 ratio (1L = 150L water)



Sanitizer



# KEY ADVANTAGES OF OUR PRODUCTS

✓ **Precision Targeting**  
Kills harmful bacteria without disrupting healthy microbiota.

✓ **Antibiotic-Free & Safe**  
Natural, non-toxic, and resistance-proof solutions.

✓ **Multi-Industry Applications**  
Pharmaceuticals, veterinary care, agriculture, and hygiene.

✓ **Clinically Approved**  
Endorsed by major medical institutions.

# INVESTMENT & GROWTH OPPORTUNITIES

## ○ **Global Market Demand**

The rise of antibiotic resistance fuels demand for bacteriophage-based solutions.

## ○ **Scalability & Commercial Expansion**

Strong R&D pipeline and potential for worldwide partnerships.

## ○ **Strategic Collaboration**

Seeking investors, distributors, and research alliances to accelerate growth.

# MILESTONES & CLINICAL ACHIEVEMENTS

2013

Aziya Immunopreparat LLC, **founded in 2013**, is one of the world's first pharmaceutical companies to produce bacteriophages for human use following GMP standards.

2016

Clinical trials of the drug "**BACTERIOPHAGE STAPHYLOCOCCAL LIQUID 'Mediphage'**" (20 ml vials) have been **successfully completed** in patients with purulent-inflammatory soft tissue diseases. Conducted by the Department of Purulent-Septic Surgery at Tashkent City Clinical Hospital No. 1.

2017

Clinical trials of "**Bacteriophage Dysentery Polyvalent Liquid 'Mediphage'**" (20 ml) for oral and rectal use were **successfully completed** by the Republican Medical Center for Epidemiology and Infectious Diseases.


2018

Clinical trials of "**Polyvalent Salmonella Bacteriophage Liquid 'Mediphage'**" (20 ml) for oral and rectal use were **successfully completed** by the Republican Medical Center for Epidemiology and Infectious Diseases.

2021

Awarded as an innovative product by the **Ministry of Innovation of the Republic of Uzbekistan**.

2022


A cooperation agreement on bacteriophage production and supply was signed with a **Saudi Arabian company**. 

2023

**2x Awarded** as an innovative product by the Ministry of Innovation of the Republic of Uzbekistan.

2023

A cooperation agreement on the production and supply of bacteriophages was signed with:

- **United States** 

- **South Korean Companies** 

2024

A cooperation agreement on the production and supply of bacteriophages was signed with:

- **German** 

- **Chinese Companies** 

2025

**11 bacteriophage-based medicinal** products were officially registered by the Ministry of Health of the Republic of Uzbekistan.

2025

**12 dietary supplements** under the brands INFEKTOFF, SANAFAG, LOROFAG, NANOFAG, and ELIFAG were officially registered.

2025

**2 veterinary products** LABIPHAGE (dry and liquid forms) were officially registered.

2025

**4 hygienic cosmetic products** were officially registered: OraxFixPhage, FemiPhage, PhageDer, and OtoIPhage.

## CERTIFICATIONS & QUALITY

**During 2022–2025**, the company successfully passed 5 GMP pharmaceutical inspections, obtained its first GMP certificate in 2022, and successfully completed re-certification in 2025.



## PATENTS & INTELLECTUAL PROPERTY

In 2025, the enterprise obtained 3 patents of the Republic of Uzbekistan for newly developed bacteriophage-based medicinal products, which are under state legal protection in accordance with the legislation of the Republic of Uzbekistan.

In addition, in accordance with the established procedure, legal protection of intellectual property results has been ensured: more than 25 intellectual property objects have been registered and protected, including trademarks issued by the Ministry of Justice of the Republic of Uzbekistan.

# Let's Connect & Innovate Together!



## Mirkamol Mirsaliev

*Co-Founder & Chief Director of  
Strategic Development*

[+998 \(97\) 767-00-28](tel:+998977670028) / [LinkedIn](#)

